Genomma Lab Internacional. de Balance Sheet Health
Financial Health criteria checks 5/6
Genomma Lab Internacional. de has a total shareholder equity of MX$10.6B and total debt of MX$6.4B, which brings its debt-to-equity ratio to 60.2%. Its total assets and total liabilities are MX$22.0B and MX$11.4B respectively. Genomma Lab Internacional. de's EBIT is MX$3.4B making its interest coverage ratio 4.4. It has cash and short-term investments of MX$1.0B.
Key information
60.2%
Debt to equity ratio
Mex$6.37b
Debt
| Interest coverage ratio | 4.4x |
| Cash | Mex$1.04b |
| Equity | Mex$10.58b |
| Total liabilities | Mex$11.41b |
| Total assets | Mex$21.98b |
Recent financial health updates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17
These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Recent updates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10
Financial Position Analysis
Short Term Liabilities: LAB B's short term assets (MX$12.0B) exceed its short term liabilities (MX$6.1B).
Long Term Liabilities: LAB B's short term assets (MX$12.0B) exceed its long term liabilities (MX$5.3B).
Debt to Equity History and Analysis
Debt Level: LAB B's net debt to equity ratio (50.5%) is considered high.
Reducing Debt: LAB B's debt to equity ratio has reduced from 76.3% to 60.2% over the past 5 years.
Debt Coverage: LAB B's debt is well covered by operating cash flow (27.7%).
Interest Coverage: LAB B's interest payments on its debt are well covered by EBIT (4.4x coverage).